Clinical Trials for Prostate Cancer
PHEN’s “Find Your Trial (FYT)” search tool connects patients with actively recruiting prostate cancer clinical trials that can possibly benefit them. The FYT tool has seven easy to use searchable categories to help patients find and review clinicals trials based on where they are on their prostate cancer journey. All trials listed have links to important information, including description, study locations, contacts and more.
All Trials
Find Your Trial
How PHEN’s Clinical Trials Navigation Hotline Can Help You
If you or a loved one has been diagnosed with prostate cancer, or if you're facing a recurrence, finding the right support and treatment options is crucial. PHEN provides multiple avenues to help individuals recently diagnosed with prostate cancer or those who have...
How can clinical researchers and pharmaceutical companies increase the diversity of their clinical trial subjects?
Many researchers and pharmaceutical companies use specific strategies to diversify their patient population to ensure that patients of all backgrounds benefit from innovative therapies and clinical studies. At PHEN’s third session of the African American Prostate...
PHEN Hosts Successful Clinical Trials Learning Session with MSKCC
On July 26, 2023, the Prostate Health Education Network (PHEN) partnered with the Memorial Sloan Kettering Cancer Center (MSKCC) for an informative Clinical Trials Learning Session. The session was spearheaded by PHEN’s Director of Clinical Trials and Patient...
PHEN to Raise Prostate Cancer Awareness at the Cotton Bowl in Dallas, TX During the Annual State Fair Classic on September 30th
September is Prostate Cancer Awareness Month and PHEN is raising prostate cancer awareness during the State Fair Classic at the famed Cotton Bowl in Dallas, Texas on September 30th. This is the Annual Football Classic between Prairie View A&M University and...
A New Era in Prostate Cancer Treatment: Embracing Second-Generation Antiandrogens
A New Era in Prostate Cancer Treatment: Embracing Second-Generation Antiandrogens Introduction: In the United States, prostate cancer is the leading cause of cancer in Black men and is the second most common cancer in all men in the United States with projections...
PHEN participated in FDA’s Black Family Cancer Awareness Week
On June 15, 2023, the US Food and Drug Administration (FDA) hosted a webinar with a panel discussion to launch Black Family Cancer Awareness Week. Dr. Keith Crawford, PHEN’s Director of Clinical Trials and Patient Education, joined the webinar. The panel consisted of...
Epigenetics: A New Hope in Fighting Prostate Cancer
Medical science is constantly advancing and discovering innovative approaches to combat diseases and enhance our well-being. One groundbreaking field making significant progress is Epigenetics. Although it may sound complex, it can be simplified as the study of how...
Patient Story: Dewayne Charleston’s Clinical Trial Participation
Dewayne Charleston is a member of PHEN’s Survivor Network who was initially diagnosed with advanced prostate cancer in 2009, and became metastatic castration resistant in 2021. Despite this serious diagnosis, Charleston persevered by pursuing clinical trials. With...
PHEN Supports Talapro-3 Clinical Trial
PHEN's Clinical Trials Rally's approach of educating Black prostate cancer patients about clinical trials, as well as strategic partnerships with pharmaceutical companies to amplify this message, is contributing to greater diversity among clinical trial participants....
The FDA approves a new prostate cancer combination treatment based upon a successful clinical trial
The U.S. Food and Drug Administration (FDA) recently approved TALZENNA (talazoparib) in combination with XTANDI (enzalutamide) for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer...
Find Your Trial
Low Risk
Intermediate Risk
High Risk
Cancer Recurrence
Non-Metastatic Castration Resistant
Metastatic Castration Sensitive
Metastatic Castration Resistant
This information is for educational purposes only and not intended as medical advice.
Patients should consult their medical doctor for advice and recommendations about specific clinical trials.